PHARMACEUTICAL COMPOSITIONS COMBINING A HYDROGENATED LIPSTATIN DERIVED AGENT AND A HMG-COA REDUCTASE INHIBITING AGENT

摘要

The invention relates to different pharmaceutical compositions comprising a synergic combination of a hydrogenated lipstatin derived agent such as the active principle orlistat and a HMG-CoA reductase enzyme inhibiting agent such as the active principles simvastatin and/or rosuvastatin, as well as pharmaceutically acceptable excipients, which are formulated in a single dosage unit for oral administration, said compositions being intended for the prevention and/or treatment of hypercholesterolaemia, triglyceridaemia, overweight and obesity.